Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compounds, as well as novel nitrated compounds and derivatives, and methods of using the derivatives in various applications.

Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compounds, as well as novel nitrated compounds and derivatives, and methods of using the derivatives in various applications.

Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compounds, as well as novel nitrated compounds and derivatives, and methods of using the derivatives in various applications.

The present disclosure provides adamantyl compounds having one or more amine groups and one or more nitrate groups. The aminoadamantyl nitrate compounds can be used to treat disorders of the central nervous system, including neurodegenerative and non-neurodegenerative diseases.

There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3α-ethynyl-3β-hydroxy-5α-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

The present disclosure provides adamantyl compounds having one or more amine groups and one or more nitrate groups. The aminoadamantyl nitrate compounds can be used to treat disorders of the central nervous system, including neurodegenerative and non-neurodegenerative diseases.

The invention relates to novel small molecule compounds having a basic structure as depicted by formula (A), where in particular exemplary embodiments R.sup.1 is —OH, R.sup.2 is —NO.sub.2 and R.sup.3 is H, R.sup.4 and R.sup.5 are H, one of R.sup.6 and R.sup.7 is selected from H, —CONH.sub.2, and —CONR.sup.9.sub.2, and the other one is selected from —CONR.sup.9.sub.2 and —CONR.sup.11R.sup.9, wherein R.sup.9 and R.sup.11 are (possibly multiply) substituted alkyl and H or alkyl, respectively. The compounds of the invention inhibit the enzyme Catechol-O-methyltransferase (COMT) and exhibit a low off-target profile. The compounds are provided for use as a medicament, in particular for use in prevention or treatment of Parkinson's disease.

The present disclosure provides adamantyl compounds having one or more amine groups and one or more nitrate groups. The aminoadamantyl nitrate compounds can be used to treat disorders of the central nervous system, including neurodegenerative and non-neurodegenerative diseases.

The present disclosure relates to compositions and methods related to bicyclo[2.2.1]heptanamine-containing compounds and salts thereof.

The present disclosure relates to compositions and methods related to bicyclo[2.2.1]heptanamine-containing compounds and salts thereof.